The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
The U.S. Food and Drug Administration (FDA) has updated the Peramivir IV Fact Sheet for Health Care Providers to revise dosing recommendations for patients with end-stage renal disease on intermittent hemodialysis and for patients with renal failure with a creatinine clearance <10 mL/min who are NOT on hemodialysis. In addition, new dosing recommendations for patients undergoing continuous renal replacement therapy (CRRT) were added. The Fact Sheet for Health Care Providers authorized by FDA on November 19, 2009 replaces the original Fact Sheet authorized on October 23, 2009. Health care providers must now use this new version of the Fact Sheet.
For more information, please visit: Peramivir Renal Dosing
This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm Monday - Friday. You can also email us at druginfo@xxxxxxxxxxx.
- For additional drug information, please visit the DDI Web page.
- For up-to-date drug information, follow the FDA’s Division of Drug Information on Twitter: FDA_Drug_Info
- This service is provided to you at no charge by the U.S. Food & Drug Administration (FDA).
Manage your FDA Subscriptions:
- Update your preferences or unsubscribe
- Questions about this service? support@xxxxxxxxxxxxxxx
- Other inquiries? webmail@xxxxxxxxxx
GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420
